Sterling Investment Advisors (Pennsylvania)’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Sterling Investment Advisors (Pennsylvania)’s Portfolio NYMX Stock Details NYMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,500	Closed	-$1K	–	571
2022 Q2	$1K	Hold	2,500	–	–	﹤0.01%	546
2022 Q1	$3K	Hold	2,500	–	–	﹤0.01%	530
2021 Q4	$3K	Hold	2,500	–	–	﹤0.01%	526
2021 Q3	$5K	Hold	2,500	–	–	﹤0.01%	489
2021 Q2	$4K	Hold	2,500	–	–	﹤0.01%	480
2021 Q1	$6K	Hold	2,500	–	–	﹤0.01%	443
2020 Q4	$6K	Hold	2,500	–	–	﹤0.01%	404
2020 Q3	$6K	Hold	2,500	–	–	﹤0.01%	376
2020 Q2	$8K	Hold	2,500	–	–	﹤0.01%	364
2020 Q1	$5K	Hold	2,500	–	–	﹤0.01%	352
2019 Q4	$5K	Hold	2,500	–	–	﹤0.01%	371
2019 Q3	$5K	Hold	2,500	–	–	﹤0.01%	374
2019 Q2	$4K	Hold	2,500	–	–	﹤0.01%	383
2019 Q1	$5K	Hold	2,500	–	–	﹤0.01%	372
2018 Q4	$3K	Hold	2,500	–	–	﹤0.01%	375
2018 Q3	$6K	Hold	2,500	–	–	﹤0.01%	377
2018 Q2	$8K	Hold	2,500	–	–	﹤0.01%	339
2018 Q1	$11K	Buy	+2,500	New	+$8.66K	0.01%	314

Other funds holding NYMX

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LSA

Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gofen & Glossberg Chicago, Illinois $3.89B AUM 11.97% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FCFC

First Citizens Financial Corp Mason City, Iowa $239M AUM 26.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Sterling Investment Advisors (Pennsylvania)'s NYMX Position: Q3 2022 in Review

Sterling Investment Advisors (Pennsylvania) sold out of Nymox Pharmaceutical Corp (NYMX) in Q3 2022, closing a stake of 2,500 shares — an estimated $1K sold.

Sterling Investment Advisors (Pennsylvania) first reported a position in NYMX in Q1 2018 and held it in 18 quarters. The position peaked at $11K in Q1 2018. 34 funds tracked by Wall St. Rank hold NYMX as of Q3 2022.

Sterling Investment Advisors (Pennsylvania) reported no remaining Nymox Pharmaceutical Corp position as of Q3 2022 after selling out during the quarter.
Sterling Investment Advisors (Pennsylvania) sold 2,500 Nymox Pharmaceutical Corp shares in Q3 2022, an estimated $1K.
Sterling Investment Advisors (Pennsylvania) first reported a position in Nymox Pharmaceutical Corp in Q1 2018 and held it in 18 quarters.
Sterling Investment Advisors (Pennsylvania)'s Nymox Pharmaceutical Corp position peaked at $11K in Q1 2018.
34 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q3 2022.

Based on Sterling Investment Advisors (Pennsylvania)'s 13F filing for Q3 2022, filed 3 Nov 2022.